Diab Yasser, Muallem Mustafa Zelal
Department of Gynecology, Portland District Hospital, Victoria, Australia.
Department of Gynecology with Center for Oncological Surgery, Campus Virchow-Klinikum, Charité Medical University, Berlin, Germany
Anticancer Res. 2017 Jun;37(6):2809-2815. doi: 10.21873/anticanres.11631.
BACKGROUND/AIM: We aimed to identify the most effectual groups of targeted therapies for ovarian cancer in recent clinical trials.
A systematic literature review has been gathered on an inventive study design that comprises of five steps. This involves search for pertinent publications from 2010 to date in various accessible medical data bases, usage of inclusion and exclusion, appraisal of quality of the studies included, abstraction of the relevant data and intelligible amalgamation of the data abridged in an evocative and narrative style.
Three types of modalities of targeted-therapy drugs have been identified; angiogenesis inhibition, signal enzymes inhibition and apoptosis induction in the tumor cells.
There has been a surge in clinical trials with drugs that specifically target signal enzymes, induce apoptosis and inhibit angiogenesis in site-specific ovarian cancer cells, which could be very promising to design a more efficacious protocol for treating the disease.
背景/目的:我们旨在确定近期临床试验中治疗卵巢癌最有效的靶向治疗药物组。
采用一种包括五个步骤的创新研究设计进行系统的文献综述。这包括在各种可获取的医学数据库中检索2010年至今的相关出版物,使用纳入和排除标准,评估纳入研究的质量,提取相关数据,并以引人入胜且具有叙述性的方式对提取的数据进行清晰的整合。
已确定三种靶向治疗药物模式;肿瘤细胞中的血管生成抑制、信号酶抑制和凋亡诱导。
针对特定部位卵巢癌细胞中信号酶、诱导凋亡和抑制血管生成的药物的临床试验激增,这对于设计更有效的治疗该疾病的方案可能非常有前景。